A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Vatiquinone (Primary)
- Indications Rett syndrome
- Focus Therapeutic Use
- Sponsors BioElectronics Corporation; Edison Pharmaceuticals
- 03 Sep 2014 Primary endpoint has not been met (Rett Syndrome Clinical Severity Score, change at six months from baseline), as reported in an Edison Pharmaceuticals media release.
- 03 Sep 2014 Results published in an Edison Pharmaceuticals media release.
- 14 Dec 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History